BRAF G466E

CI-VAR-00001746Explore in graph →NP_001341538.1:p.Gly466GluNM_001354609.2:c.1397G>AClinVar 376073 CIViC 2792 rs121913351

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
HRAS Q61K AND BRAF G466E	Cetuximab	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID12447 Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
HRAS Q61K AND BRAF G466E	Trametinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12454 Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The melanoma cell line, SK-MEL-208 (BRAF G466E + HRAS Q61K), was sensitive with a low I… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376073	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	RASopathy; Noonan syndrome 7; Epidermal nevus; Embryonal rhabdomyosarcoma	germline/somatic	4	May 25, 2025	clinvar

Solid Neoplasm1
BRAF G466E	Vemurafenib	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID7555 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic